EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort

Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte rat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancers (Basel)
Päätekijät: Prelaj, Arsela, Ferrara, Roberto, Rebuzzi, Sara Elena, Proto, Claudia, Signorelli, Diego, Galli, Giulia, De Toma, Alessandro, Randon, Giovanni, Pagani, Filippo, Viscardi, Giuseppe, Brambilla, Marta, Trevisan, Benedetta, Ganzinelli, Monica, Martinetti, Antonia, Gallucci, Rosaria, Di Mauro, Rosa Maria, Molino, Giuliano, Zilembo, Nicoletta, Torri, Valter, de Braud, Filippo Maria, Garassino, Marina Chiara, Lo Russo, Giuseppe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6966664/
https://ncbi.nlm.nih.gov/pubmed/31817541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11121954
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia